{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:24:38Z","timestamp":1772778278579,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Venetoclax combined with low-intensity chemotherapy has led to longer survival and higher remission rates in patients with untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy. We reviewed 41 newly diagnosed and relapse\/refractory acute myeloid leukaemia patients who received venetoclax at our institute. Complete remission or complete remission with incomplete recovery was achieved in 73.1% of patients. A total of 95.1% of patients discontinued venetoclax, mainly because of severe cytopenia, disease progression and haematopoietic stem cell transplantation. The median number of courses of venetoclax was 2. In all, 92.6% of the patients experienced grade\u00a0\u2265\u00a03 neutropenia. The median overall survival was 287\u00a0days. Venetoclax dose reduction resulted in better continuity of treatment with fewer complications. In conclusion, venetoclax and low-intensity chemotherapy led to high remission rates, but survival was restrained because of the large number of venetoclax discontinuations. Dose reduction of venetoclax may mitigate cytopenia while maintaining efficacy.<\/jats:p>","DOI":"10.1093\/jjco\/hyad075","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T06:49:56Z","timestamp":1688366996000},"page":"991-995","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of venetoclax for acute myeloid leukaemia in real-world clinical practice"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1079-6888","authenticated-orcid":false,"given":"Ami","family":"Fukumoto","sequence":"first","affiliation":[{"name":"Kameda Medical Center Division of Hematology\/Oncology, Department of Internal Medicine, , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-9046","authenticated-orcid":false,"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[{"name":"Kameda Medical Center Division of Hematology\/Oncology, Department of Internal Medicine, , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7398-4616","authenticated-orcid":false,"given":"Daisuke","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Kameda Medical Center Division of Hematology\/Oncology, Department of Internal Medicine, , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Uesugi","sequence":"additional","affiliation":[{"name":"Kameda Medical Center Division of Hematology\/Oncology, Department of Internal Medicine, , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikako","family":"Tabata","sequence":"additional","affiliation":[{"name":"Kameda Medical Center Division of Hematology\/Oncology, Department of Internal Medicine, , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Miura","sequence":"additional","affiliation":[{"name":"Kameda Medical Center Division of Hematology\/Oncology, Department of Internal Medicine, , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Kameda Medical Center Division of Hematology\/Oncology, Department of Internal Medicine, , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8669-9865","authenticated-orcid":false,"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[{"name":"Kameda Medical Center Division of Hematology\/Oncology, Department of Internal Medicine, , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"2023100417311991800_ref1","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"2023100417311991800_ref2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100417311991800_ref3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023100417311991800_ref4","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"2023100417311991800_ref5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"2023100417311991800_ref6","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"2023100417311991800_ref7","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv"},{"key":"2023100417311991800_ref8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","article-title":"Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US","volume":"27","author":"Vachhani","year":"2022","journal-title":"Oncologist"},{"key":"2023100417311991800_ref9","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"key":"2023100417311991800_ref10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"key":"2023100417311991800_ref11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.26190","article-title":"Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice","volume":"96","author":"Apel","year":"2021","journal-title":"Am J Hematol"},{"key":"2023100417311991800_ref12","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"2023100417311991800_ref13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jjco\/hyab170","article-title":"Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy","volume":"52","author":"Yamamoto","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2023100417311991800_ref14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12032-022-01865-y","article-title":"Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia","volume":"39","author":"Kobayashi","year":"2022","journal-title":"Med Oncol"},{"key":"2023100417311991800_ref15","doi-asserted-by":"crossref","first-page":"e8933","DOI":"10.1371\/journal.pone.0008933","article-title":"The average body surface area of adult cancer patients in the UK: a multicentre retrospective study","volume":"5","author":"Sacco","year":"2010","journal-title":"PloS One"},{"key":"2023100417311991800_ref16","doi-asserted-by":"crossref","first-page":"204062071988282","DOI":"10.1177\/2040620719882822","article-title":"Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy","volume":"10","author":"Richard-Carpentier","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"2023100417311991800_ref17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"2023100417311991800_ref18","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00277-023-05201-w","article-title":"Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia","volume":"102","author":"Gando","year":"2023","journal-title":"Ann Hematol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/10\/991\/51848964\/hyad075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/10\/991\/51848964\/hyad075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T17:32:04Z","timestamp":1696440724000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/10\/991\/7216773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,7,1]]},"published-print":{"date-parts":[[2023,10,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad075","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,7,1]]}}}